Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Alzheimer's Research & Therapy 11 (2019).
- Event
-
Veröffentlichung
- (where)
-
Erlangen
- (who)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (when)
-
2019
- Creator
- URN
-
urn:nbn:de:bvb:29-opus4-121416
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hansson, Oskar
- Lehmann, Sylvain
- Otto, Markus
- Zetterberg, Henrik
- Lewczuk, Piotr
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Time of origin
- 2019
Other Objects (12)
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
The neuropathological diagnosis of Alzheimer’s disease
The endotoxin hypothesis of Alzheimer’s disease
The neuroimmune axis of Alzheimer’s disease
Predicting the course of Alzheimer’s progression
The plasma peptides of Alzheimer’s disease
Quantifying Knowledge of Alzheimer’s Disease: An Analysis of the Psychometric Properties of the Alzheimer’s Disease Knowledge Scale
Facing the future of Alzheimer’s disease: the value of the medical laboratory
Complement in the pathogenesis of Alzheimer’s disease
Measuring knowledge of Alzheimer’s: development and psychometric testing of the UJA Alzheimer’s Care Scale
The dynamics of plasma biomarkers across the Alzheimer’s continuum
The immune system on the TRAIL of Alzheimer’s disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
The neuropathological diagnosis of Alzheimer’s disease
The endotoxin hypothesis of Alzheimer’s disease
The neuroimmune axis of Alzheimer’s disease
Predicting the course of Alzheimer’s progression
The plasma peptides of Alzheimer’s disease
Quantifying Knowledge of Alzheimer’s Disease: An Analysis of the Psychometric Properties of the Alzheimer’s Disease Knowledge Scale
Facing the future of Alzheimer’s disease: the value of the medical laboratory
Complement in the pathogenesis of Alzheimer’s disease
Measuring knowledge of Alzheimer’s: development and psychometric testing of the UJA Alzheimer’s Care Scale
The dynamics of plasma biomarkers across the Alzheimer’s continuum
The immune system on the TRAIL of Alzheimer’s disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
The neuropathological diagnosis of Alzheimer’s disease
The endotoxin hypothesis of Alzheimer’s disease
The neuroimmune axis of Alzheimer’s disease
Predicting the course of Alzheimer’s progression
The plasma peptides of Alzheimer’s disease
Quantifying Knowledge of Alzheimer’s Disease: An Analysis of the Psychometric Properties of the Alzheimer’s Disease Knowledge Scale
Facing the future of Alzheimer’s disease: the value of the medical laboratory
Complement in the pathogenesis of Alzheimer’s disease
Measuring knowledge of Alzheimer’s: development and psychometric testing of the UJA Alzheimer’s Care Scale
The dynamics of plasma biomarkers across the Alzheimer’s continuum